• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Prometrika and Boston Biotech Clinical Research Help Sponsors Create DMCs

Prometrika and Boston Biotech Clinical Research Help Sponsors Create DMCs

December 15, 2009
CenterWatch Staff

Contract research organization (CRO) Prometrika and medical research consulting firm Boston Biotech Clinical Research (BBCR) are teaming up to provide data monitoring committee (DMC) services to clinical trial sponsors.  Together, the companies will help sponsors establish and operate independent DMCs (also called data safety monitoring boards and data and safety monitoring committees).

Sometimes required by the FDA, DMCs help protect the safety of patients and the validity of clinical trial results by providing independent review of safety and efficacy data collected during clinical research.

Prometrika and BBCR will help sponsors recruit DMC participants, develop DMC charters and analysis plans, prepare reports and coordinate DMC meetings. The companies will also offer independent statistical analysis of data and safety monitoring.

 “While Prometrika has served as the data analysis center for a number of DMCs during the past seven years, our new DMC service is uniquely positioned to deliver the levels of precision, flexibility and independence that biopharmaceutical companies need to support the full range of requirements for safety monitoring and interim data analysis in clinical research,” said Miganush Stepanians, Ph.D., president and CEO of Prometrika.

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing